| 摘要 |
PROBLEM TO BE SOLVED: To provide a novel benzoquinolone compound having a vesicle monoamine transporter 2 (VMAT2) inhibitory action, and capable of avoiding side effects accompanying oxidative metabolism observed in dihydrotetrabenazine which is an existing medication.SOLUTION: A compound is obtained by substituting deuterium atoms for 1 or more hydrogen atoms on ring carbon atoms and side chain carbon atoms of dihydrotetrabenazine represented by a following compound. The compound has a VMAT2 inhibitory action, and is useful for therapy of chronic hypermotility disease, Huntington disease, hemiballism, senile chorea, tic disorder, delayed dyskinesia, dystonia, Tourette syndrome, depression, cancer, articular rheumatism, mental disease, multiple sclerosis, asthma, and the like.SELECTED DRAWING: None |
